© 2017 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#ICAAC 2008

Click Here for More Conferences
Click Here for ICAAC Online
HIV: The Basics
The U.N. General Assembly Hall during the High-level Meeting on HIV/AIDS.

Conferences

Drug-Resistant Staph and HIV - Part 2

At the 2008 joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society...

Drug-Resistant Staph and HIV - Part 1

At the 2008 joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society o...

Drug-Resistant Staph: Growing Concern Among People With HIV

Skin infections caused by drug-resistant staph are more common and more likely to recur in people living with HIV, according to three new stud...

High Number of Pulmonary Hypertension Cases in Naval HIV Cohort Study

The incidence of pulmonary hypertension—high blood pressure in the arteries that supply the lungs—is significantly higher in HIV-p...

Truvada vs. Epzicom: The Debate Goes On

A handful of presentations at the 2008 joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the I...

Long-Term Benefits and Risks of Kaletra Monotherapy Explored in Two Studies

More than 10 years after combination HIV treatment was heralded as the one and only way to treat HIV, data continue to emerge suggesting that...

Has HIV Evolved to Become More Dangerous?

Twenty-five years into the HIV epidemic, has the virus evolved to become more dangerous? This was the question asked by a research team headed...

Higher Response Rate with Norvir-Boosted Reyataz vs. Kaletra as First-Line Therapy

Long-term follow-up data from a study indicate higher response rates with Norvir (ritonavir)-boosted Reyataz (atazanavir) compared with Kaletr...

Greater HIV Response to Prezista vs. Kaletra for First-Timers Over 96 Weeks

Once-daily Norvir (ritonavir)-boosted Prezista (darunavir) is more likely to keep viral loads undetectable in HIV-positive people starting ant...

PRO 140 Has Long-Lasting Activity Against HIV

Positive early results from a Phase II clinical trial of intravenous (IV) PRO 140, an experimental HIV entry inhibitor.

New NNRTI Called RDEA806 Shows Promise

Once-daily RDEA806, an experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed by Ardea Biosciences, appears highl...

Should ARV Treatment Be Started When CD4s Fall Below 500?

New research from a team of U.S. and Canadian researchers suggests that HIV-positive people have less risk of dying if they start ARV...

Selzentry Reanalysis Shows Potential as First-Line Treatment

Selzentry (Celsentri; maraviroc) is comparable to Sustiva (efavirenz) in HIV-positive patients starting antiretroviral (ARV) treatment for the...

Isentress Comparable to Sustiva for First-Time Treatment

Isentress (raltegravir) appears to work just as well as Sustiva (efavirenz), with fewer drug-related side effects, in HIV-positive patients st...
Advertisement
Newsfeed
Treatment News
Exclusives
Opinions